New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes

A new analysis presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAI